The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib response prediction in metastatic colorectal cancer by a novel genomic and transcriptomic model.
 
Andreas Seeber
No Relationships to Disclose
 
Marwa Abdel-Hamid
No Relationships to Disclose
 
Arno Amann
No Relationships to Disclose
 
Lorenz Pammer
No Relationships to Disclose
 
Andrew Elliott
Employment - Caris Life Sciences
 
Kieran Sweeney
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
George Sledge
Employment - Caris Life Sciences
Leadership - Caris Life Sciences; Syndax
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Piotr Tymoszuk
No Relationships to Disclose
 
Martin Pichler
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Abbvie; Adagene; Bayer; Boehringer Ingelheim; Fulgent Genetics; Janssen Oncology; Jazz Pharmaceuticals; Merck Serono; Merus; Roche
Consulting or Advisory Role - 3T BioSciences; Abbvie; Adagene; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Wafik El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Research Funding - Chimerix
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences
 
Emil Lou
Stock and Other Ownership Interests - Ryght
Honoraria - Boston Scientific; Colorectal Cancer Alliance; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Benjamin Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Caris Life Sciences; Primum
Consulting or Advisory Role - Agenus; AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; Foundation Medicine; Merus NV; Regeneron
Speakers' Bureau - Bayer; Daiichi Sankyo/Astra Zeneca; Jazz Pharmaceuticals; Merus NV; Natera; Pfizer; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding - BioXCel therapeutics (Inst); Immune System Key (Inst); Ipsen (Inst); Merck (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Merus NV
 
David Hsieh
Research Funding - Arcus Biosciences (Inst)
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; BMS; Erasca, Inc; Pfizer
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Accent Therapeutics; Alentis Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Carina Biotech; Cartography Biosciences; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; Lilly; Menarini; Merus; MSD; Novartis; Ono Pharmaceutical; Peptomyc; Pfizer; Pierre Fabre; Quantro Therapeutics; Scandion Oncology; Scorpion Therapeutics; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem Therapeutics; Autem therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Incyte (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)
 
Moh'd Khushman
Stock and Other Ownership Interests - Cardiff Oncology
Consulting or Advisory Role - Abbvie; bristol-myers squibb; Cardinal Health; Elevar Therapeutics; Exelixis; Muerus; TriSalus Life Sciences
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbvie (Inst); FOGPharma (Inst); IgM Biosciences (Inst); Torl Biotherapeutics (Inst)
 
Dominik Wolf
No Relationships to Disclose
 
Jakob Riedl
No Relationships to Disclose